ImmuPharma (LON:IMM) Trading 24.8% Higher – Still a Buy?

Shares of ImmuPharma plc (LON:IMM) shot up 24.8% during trading on Friday . The company traded as high as GBX 2.57 ($0.03) and last traded at GBX 2.56 ($0.03). 7,743,507 shares traded hands during trading, an increase of 16% from the average session volume of 6,650,066 shares. The stock had previously closed at GBX 2.05 ($0.03).

ImmuPharma Trading Up 11.2%

The company has a market cap of £9.69 million, a PE ratio of -3.94 and a beta of 1.53. The business’s 50 day moving average is GBX 2.52 and its two-hundred day moving average is GBX 3.04.

ImmuPharma (LON:IMM) last announced its quarterly earnings results on Monday, May 19th. The company reported GBX (0.60) (($0.01)) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. As a group, equities research analysts predict that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.